Redefining Readiness: Are We Prepared for the Bispecific Era in Multiple Myeloma?

An expert discusses how bispecific antibodies are reshaping the treatment landscape for relapsed/refractory multiple myeloma (R/R MM) by offering off-the-shelf, effective alternatives to CAR T-cell therapy, while emphasizing the need for institutional planning, patient monitoring, and coordinated care to manage continuous therapy, adverse effects, and resource demands.

An expert discusses the evolving role of BCMA-targeted therapies in relapsed/refractory multiple myeloma (R/R MM), comparing the efficacy, safety, and logistical considerations of CAR T-cell therapies, bispecific antibodies, and antibody-drug conjugates, and emphasizing the importance of individualized treatment selection and ongoing refinement of therapeutic sequencing.

An expert discusses how treatment guidelines and institutional pathways are evolving to integrate CAR T-cell therapies and bispecific antibodies for relapsed/refractory multiple myeloma (R/R MM), emphasizing individualized sequencing decisions, logistical considerations, and the critical role of patient and caregiver education in optimizing outcomes with bispecific therapy

An expert discusses the growing importance of real-world evidence in informing payer decisions and value-based care strategies for bispecific therapies in relapsed/refractory multiple myeloma (R/R MM), highlighting the need to validate clinical trial outcomes, assess economic impact, and ensure equitable integration into treatment pathways.

An expert discusses the approval of a third bispecific antibody for relapsed/refractory multiple myeloma (R/R MM), highlighting its potential to reshape treatment pathways, intensify payer scrutiny around formulary positioning and cost-effectiveness, and drive a more competitive, real-world reassessment of the bispecific therapy class.

An expert discusses the operational and financial complexities of integrating bispecific antibodies into multiple myeloma treatment pathways, emphasizing the need for standardized protocols, multidisciplinary training, payer-provider collaboration, and infrastructure investments to support safe, scalable, and value-based delivery of care.

An expert discusses the evolving role of bispecific antibodies in multiple myeloma, highlighting their off-the-shelf availability, immune-targeting mechanism, and growing potential in relapsed and frontline settings, while emphasizing the need for proactive toxicity management, personalized supportive care, and strategic integration into broader treatment plans.